Annovis Bio Pushes Alzheimer's Phase 3 Readout to March 2027, Rolling NDA Conditional on Efficacy

What happened

Annovis Bio announced that top-line results from the six-month portion of its pivotal Phase III Alzheimer's trial are now expected in March 2027, a delay from the previous guidance of second-half 2026. The company is simultaneously preparing a rolling New Drug Application (NDA) that could begin in May 2027 if the trial meets its efficacy requirements. This timeline extension exacerbates the company's precarious financial position, as it had only $15.3 million in cash as of September 2025, with a monthly burn of approximately $2 million and a disclosed cash runway only into the third quarter of 2026. Consequently, Annovis will need multiple additional financing rounds well before the data readout, likely at increasingly dilutive terms given its NYSE listing compliance issues and going-concern warnings. The delay reduces the near-term value proposition, as investors now face a longer period of binary risk with no clinical catalysts for at least another year and a half.

Implication

The push of the Alzheimer's Phase 3 readout to March 2027 means that Annovis will need to raise substantial capital to bridge the gap between its current cash runway (ending Q3 2026) and the data announcement. Given the company's tiny market capitalization, heavy warrant overhang, and NYSE listing non-compliance, any new equity financing is likely to be highly dilutive and may include punitive terms. Even if the company successfully funds the trial, the outcome remains binary: the rolling NDA initiation is contingent on efficacy, and Alzheimer's trials have high failure rates. This setup suggests that long-term upside, if buntanetap works, will accrue to a much larger share count, reducing per-share returns relative to earlier expectations. Therefore, existing shareholders should consider trimming or hedging positions, while potential new investors may prefer to wait for either a significant de-risking event (e.g., partnership, successful financing at reasonable terms) or a lower valuation entry point.

Thesis delta

The previous thesis assumed a six-month Phase 3 readout in H2 2026, but that has now slipped to March 2027, pushing the pivotal event beyond the company's projected cash runway. This shift materially increases the probability of multiple dilutive financings before any data catalyst, heightening the risk of catastrophic share count expansion or even insolvency. Consequently, the investment thesis shifts further toward a pure speculative option, with reduced probability of realizing value without severe capital structure damage.